Omalizumab in patients with severe asthma: The XCLUSIVE study

Clinical Respiratory Journal

Volumn 6, Issue 4, 2012, Pages 215-227

  Schumann, Christian ^a   Kropf, Cornelia ^a   Wibmer, Thomas ^a   Rüdiger, Stefan ^a   Stoiber, Kathrin Magdalena ^a   Thielen, Antje ^b   Rottbauer, Wolfgang ^a   Kroegel, Claus ^c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Novartis Pharmacy   (Germany)

^c Department of Pneumology and Allergy   (Germany)

Author keywords

Omalizumab; Real life experience; Safety; Severe persistent asthma

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

ABSENTEEISM; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CHILD; CLINICAL PRACTICE; CONNECTIVE TISSUE DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; EYE DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; GERMANY; HEART DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INJURY; INTOXICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SKIN DISEASE; TREATMENT RESPONSE; URTICARIA; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY FLOW RATES; GENERAL PRACTICE; GERMANY; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866152237     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2011.00263.x     Document Type: Article

References (32)

1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5): 469-78.
2. D'Amato G, Cecchi L. Effects of climate change on environmental factors in respiratory allergic diseases. Clin Exp Allergy. 2008;38(8): 1264-74.
3. D'Amato G, Liccardi G, D'Amato M, Holgate S. Environmental risk factors and allergic bronchial asthma. Clin Exp Allergy. 2005;35(9): 1113-24.
4. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22(3): 470-7.
5. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115(3): 459-65.
6. Bateman ED, Hurd SS, Barnes PJ, etal. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1): 143-78.
7. Sears M, Burrows B, Flannery E, Herbison G, Hewitt C, Holdaway M. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med. 1991;325(15): 1067-71.
8. Burrows B, Martinez F, Halonen M, Barbee R, Cline M. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320(5): 271-7.
9. Coyle A, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med. 1996;183(4): 1303-10.
10. Kroegel C, Foerster M. Omalizumab. In: Dübel S, editor. Handbook of Therapeutic Antibodies, 1st edn. Weinheim, Wiley-VCH, 2007: 951-97.
11. Humbert M, Beasley R, Ayres J, etal. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3): 309-16.
12. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4): 902-7.
13. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103: 1725-31.
14. Soler M, Matz J, Townley R, etal. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2): 254-61.
15. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125(4): 1378-86.
16. Buhl R, Soler M, Matz J, etal. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20(1): 73-8.
17. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med. 2008;102(10): 1371-8.
18. Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2008;102(1): 71-6.
19. Price D. The use of omalizumab in asthma. Prim Care Respir J. 2008;17(2): 62-72.
20. Bousquet J, Cabrera P, Berkman N, etal. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60(3): 302-8.
21. Busse W, Corren J, Lanier BQ, etal. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2): 184-90.
22. Holgate ST, Chuchalin AG, Hebert J, etal. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4): 632-8.
23. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2): 154-9.
24. Vignola AM, Humbert M, Bousquet J, etal. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7): 709-17.
25. Bousquet J, Rabe K, Humbert M, etal. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7): 1483- 92.
26. Thier SL, Yu-Isenberg KS, Leas BF, etal. In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. Manag Care. 2008;17(2): 48-52. 55-7.
27. Brusselle G, Michils A, Louis R, etal. 'Real-life' effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103: 1633-42.
28. Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy. 2009;64: 1780-7.
29. Beeh KM, Beier J, Buhl R. Seasonal variations of serum-IgE and potential impact on dose-calculation of omalizumab (rhuMab-E25, anti-IgE). Pneumologie. 2004;58(8): 546-51.
30. Hochhaus G, Brookman L, Fox H, etal. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19(6): 491-8.
31. Johansson SG, Oman H, Nopp A, Pettersson S. The importance of IgE antibody levels in anti-IgE treatment. Allergy. 2006;61(10): 1216-9.
32. Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy. 2009;64(1): 81-4.